mRNA Vaccine for Tuberculosis Prevention Offers New Possibilities
Deficient Vaccine, the Shadow of TB
Globally, tuberculosis (TB) mortality remains high, and the existing Bacillus Calmette-Guérin (BCG) vaccine shows markedly variable efficacy across regions. Mycobacterium tuberculosis (Mtb) resides intracellularly and hides within necrotic granulomas in the lung, limiting immune cell access. This characteristic creates an urgent need for new preventive strategies.
Immune Warfare Reengineered with mRNA
The mRNA vaccine platform enables in vivo antigen production, robustly activating CD8⁺ T cells. It also allows the design of multi‑stage fusion antigens that can target both active and latent phases, providing flexibility. The manufacturing process is rapid and readily scalable, making large‑scale distribution feasible.
Limitations and Breakthrough: Pulmonary Mucosal Delivery
However, mRNA alone cannot readily penetrate the granulomas formed by Mtb, and systemic immunity experiences a "recruitment lag" before reaching the lung parenchyma. Overcoming this requires a mucosal delivery system that induces immunity directly at the airway surface. Current research is exploring lipid nanoparticle (LNP)‑based inhalants and intranasal spray formulations.
New Hope, Future Preventive Strategies
If pulmonary mucosal delivery succeeds, sterile protection may be achievable, fundamentally shifting TB prevention strategies. Ongoing clinical trials and manufacturing optimization could bring transformative change to global health.
The persistent global burden of tuberculosis (TB) and the context-dependent efficacy of the Bacillus Calmette-Guérin (BCG) vaccine necessitate the development of innovative prophylactic strategies. mRNA vaccine platforms have emerged as a transformative toolkit, offering unprecedented versatility in antigen design and manufacturing scalability. This inclusive innovation review synthesizes the molecular engineering and immunological mechanisms of mRNA TB vaccines, evaluating their capacity to address the unique challenges posed by the intracellular lifestyle of Mycobacterium tuberculosis (Mtb). mRNA platforms realistically offer superior endogenous antigen production for CD8⁺ T-cell activation and the flexibility to encode multi-stage fusion antigens targeting both active and latent bacilli. However, significant constraints remain; mRNA technology alone cannot resolve the spatial sequestration of Mtb within necrotic granulomas or the "recruitment lag" of systemic immunity to the lung parenchyma. Achieving sterile protection requires a transition toward mucosal delivery systems capable of inducing lung T
The core issue addressed by this research is the variable efficacy of the existing Bacillus Calmette-Guérin (BCG) vaccine and the persistent mortality caused by tuberculosis. A more effective preventive vaccine could reduce the risk of TB infection in everyday life and improve public health.